| 翻訳と辞書 |
Simeprevir
Simeprevir (formerly TMC435; trade names Olysio and Sovriad) is a drug for the treatment and cure of hepatitis C.〔(News: United States to approve potent oral drugs for hepatitis C ), Sara Reardon, Nature, 30 October 2013〕 It was developed by Medivir and Johnson & Johnson's pharmaceutical division Janssen Pharmaceutica. In the United States, simeprevir is approved by the Food and Drug Administration for use in combination with peginterferon-alfa and ribavirin for hepatitis C.〔(【引用サイトリンク】 FDA approves new treatment for hepatitis C virus )〕 Simeprevir has been approved in Japan for the treatment of chronic hepatitis C infection, genotype 1.〔(【引用サイトリンク】 Medivir: Simeprevir has been approved in Japan for the treatment of genotype 1 chronic hepatitis C infection )〕
==Medical use==
Simeprevir is indicated treating chronic hepatic C (CHC) infection as a part of a triple antiviral treatment regimen consisting of two other drugs: peginterferon-alfa (PEG-IFN) and ribavirin (RBV).〔(【引用サイトリンク】title=OLYSIO (simeprevir) capsules, for oral use FULL PRESCRIBING INFORMATION )〕 It is primarily efficacious in treating Hepatitis C virus (HCV) genotype 1 infected subjects with compensated liver disease, including cirrhosis.〔 There are currently no studies that show Simeprevir’s effectiveness as a single therapy for HCV.〔 Simeprevir is generally used for HCV genotype 1 infected subjects, but off-label medical use has been indicated for type 4 genotype as well.〔(【引用サイトリンク】title=Recommendations for Testing, Managing, and Treating Hepatitis C )〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Simeprevir」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|